JPH05201862A - 増殖性疾患の治療のためのジピリダモル - Google Patents

増殖性疾患の治療のためのジピリダモル

Info

Publication number
JPH05201862A
JPH05201862A JP4308615A JP30861592A JPH05201862A JP H05201862 A JPH05201862 A JP H05201862A JP 4308615 A JP4308615 A JP 4308615A JP 30861592 A JP30861592 A JP 30861592A JP H05201862 A JPH05201862 A JP H05201862A
Authority
JP
Japan
Prior art keywords
dipyridamole
formulation
site
growth
local delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP4308615A
Other languages
English (en)
Japanese (ja)
Inventor
Raymond F Kauffman
レイモンド・フランシス・カウフマン
Jai Pal Singh
ジャイ・パル・シン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH05201862A publication Critical patent/JPH05201862A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP4308615A 1991-11-21 1992-11-18 増殖性疾患の治療のためのジピリダモル Withdrawn JPH05201862A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/795,434 US5270047A (en) 1991-11-21 1991-11-21 Local delivery of dipyridamole for the treatment of proliferative diseases
US795434 1991-11-21

Publications (1)

Publication Number Publication Date
JPH05201862A true JPH05201862A (ja) 1993-08-10

Family

ID=25165502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4308615A Withdrawn JPH05201862A (ja) 1991-11-21 1992-11-18 増殖性疾患の治療のためのジピリダモル

Country Status (12)

Country Link
US (2) US5270047A (OSRAM)
EP (1) EP0543653A1 (OSRAM)
JP (1) JPH05201862A (OSRAM)
KR (1) KR930009607A (OSRAM)
AU (1) AU661067B2 (OSRAM)
CA (1) CA2083223A1 (OSRAM)
HU (1) HU212422B (OSRAM)
MX (1) MX9206610A (OSRAM)
NO (1) NO924461L (OSRAM)
RU (1) RU2084224C1 (OSRAM)
TW (1) TW252917B (OSRAM)
ZA (1) ZA928832B (OSRAM)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994016706A1 (en) * 1993-01-28 1994-08-04 Neorx Corporation Therapeutic inhibitors of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
PT1155689E (pt) * 1993-07-19 2007-01-31 Angiotech Pharm Inc Composições anti-angiogenicas e metodos de utilização
US5521191A (en) * 1994-10-17 1996-05-28 Washington University Method for treatment of arterial stenosis
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US7846202B2 (en) 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
CA2178541C (en) * 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US7867275B2 (en) * 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US20070203520A1 (en) * 1995-06-07 2007-08-30 Dennis Griffin Endovascular filter
US5951586A (en) * 1996-05-15 1999-09-14 Medtronic, Inc. Intraluminal stent
ES2248847T3 (es) 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US6530951B1 (en) 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
WO1999009912A1 (en) 1997-08-26 1999-03-04 Technion Research And Development Foundation Ltd. Intravascular apparatus and method
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) * 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
RU2157199C2 (ru) * 1998-04-03 2000-10-10 Вахрушев Яков Максимович Способ лечения хронического панкреатита
DE69926017T2 (de) 1998-04-27 2005-12-22 SurModics, Inc., Eden Prairie Bioaktive Wirkstoffe freisetzende Beschichtungen
US6299604B1 (en) 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
US6168619B1 (en) * 1998-10-16 2001-01-02 Quanam Medical Corporation Intravascular stent having a coaxial polymer member and end sleeves
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
EP1250166B1 (en) 2000-01-25 2010-03-17 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
JP2004511297A (ja) 2000-10-16 2004-04-15 コナー　メドシステムズ，　インコーポレイテッド 有益な薬剤を搬送するための拡張可能な医療装置
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7064130B2 (en) 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
DE10119680A1 (de) * 2001-04-20 2002-11-14 Boehringer Ingelheim Pharma Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
EP1448205B1 (en) * 2001-10-05 2011-03-23 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
US20030077310A1 (en) * 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US20030083614A1 (en) * 2001-10-30 2003-05-01 Boehringer Ingelheim Pharma Kg Controlled release endoprosthetic device
EP1308179A1 (en) * 2001-10-30 2003-05-07 Boehringer Ingelheim Pharma GmbH & Co.KG Improved endoprosthetic device
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
CA2472188C (en) * 2002-01-18 2011-06-21 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US10441747B2 (en) 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
US7744584B2 (en) 2002-01-22 2010-06-29 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US20030171734A1 (en) * 2002-01-22 2003-09-11 Endobionics, Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
ATE495769T1 (de) * 2002-07-12 2011-02-15 Cook Inc Beschichtete medizinische vorrichtung
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US20040162542A1 (en) * 2002-12-03 2004-08-19 Endobionics, Inc. Methods and systems for treating the vasculature with estrogens
WO2004069254A2 (en) * 2003-02-07 2004-08-19 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
AU2004226327A1 (en) 2003-03-28 2004-10-14 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1740235B1 (en) 2004-04-06 2009-07-22 SurModics, Inc. Coating compositions for bioactive agents
WO2007139753A2 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
EP2231129A4 (en) * 2007-12-17 2013-01-30 Zalicus Inc THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
JP6989597B2 (ja) 2016-09-22 2022-01-05 マーケイター メドシステムズ， インコーポレイテッド テムシロリムスを使用する再狭窄の処置
CN110996687A (zh) 2017-05-26 2020-04-10 墨卡托医疗系统公司 用于治疗再狭窄的联合疗法
WO2019178231A1 (en) 2018-03-14 2019-09-19 Mercator Medsystems, Inc. Medical instrument and medical method for localized drug delivery
WO2021077070A1 (en) * 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
CN113244395B (zh) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1208516A (en) * 1982-04-02 1986-07-29 Harvey Wolinsky Methods and apparatus for relieving arterial constrictions
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
EP0431046B1 (en) * 1988-08-24 1995-05-03 SLEPIAN, Marvin J. Biodegradable polymeric endoluminal sealing
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
ES2078936T3 (es) * 1989-01-31 1996-01-01 Bard Inc C R Cateter y metodo para aplicar localmente la medicacion a la pared de un vaso sanguineo o de otro lumen corporal.
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors

Also Published As

Publication number Publication date
US5314688A (en) 1994-05-24
AU661067B2 (en) 1995-07-13
KR930009607A (ko) 1993-06-21
AU2845492A (en) 1993-05-27
CA2083223A1 (en) 1993-05-22
NO924461D0 (no) 1992-11-19
HU212422B (en) 1996-06-28
US5270047A (en) 1993-12-14
HU9203626D0 (en) 1993-01-28
EP0543653A1 (en) 1993-05-26
TW252917B (OSRAM) 1995-08-01
RU2084224C1 (ru) 1997-07-20
MX9206610A (es) 1993-05-01
HUT70034A (en) 1995-09-28
ZA928832B (en) 1994-05-16
NO924461L (no) 1993-05-24

Similar Documents

Publication Publication Date Title
US5314688A (en) Local delivery of dipyridamole for the treatment of proliferative diseases
US5599844A (en) Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Douglas et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670.
US6429232B1 (en) Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
Edelman et al. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury.
US6544541B1 (en) Devices and compounds for treating arterial restenosis
Fishbein et al. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis
Mayberg et al. Radiation inhibition of intimal hyperplasia after arterial injury
RU2322984C2 (ru) Комбинации для лечения иммуновоспалительных расстройств
WO1995003795A9 (en) Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
JP2003533493A (ja) 再狭窄の予防に有効な薬剤の組み合わせ
EP0363671B1 (de) Verwendung von ACE-Inhibitoren gegen Neointimabildung nach Gefässverletzung
JPH10507449A (ja) 血管再狭窄阻害用医薬の製造のためのザプリナストの使用
US20080085293A1 (en) Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
Matsumura et al. Intravesical chemotherapy with 4′-epi-Adriamycin in patients with superficial bladder tumors
DE69921980T2 (de) Periadventitiales verabreichungssystem
Sharpe et al. Anesthetic considerations for the previously transplanted patient
Coats et al. Inhibition of non-Ras protein farnesylation reduces in-stent restenosis
Pazdur et al. Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model
KR100987557B1 (ko) 혈관 재협착 치료 또는 예방용 조성물
RU2751649C1 (ru) Способ лечения и профилактики цистита
US6498152B1 (en) Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis
Jung et al. Perivascular delivery of rapamycin in pluronic gel inhibits neointimal hyperplasia in a rat carotid artery injury model, and the complementary role of carotid arteriography
Low et al. Role of cimetidine in the prevention of intimal hyperplasia in rat carotid artery
DE102007016283A1 (de) Verwendung von 2-Deoxy-D-Glucose zur Verhinderung oder Behandlung von Arteriosklerose und Arteriothrombose

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20000201